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THE PUBLIC HEALTH PERSPECTIVE SCREENING, i.e. early detection before a clinical diagnosis is made on the basis of symptoms, has been proposed for cancers at many sites (see [l] for an overview). The goal of population screening is to reduce the burden of the cancer in terms of morbidity and mortality. In this respect, it is just one of several possible interventions and should be compared with the other alternatives: primary prevention, early case finding, treatment, rehabilitation and terminal care. In judging screening, however, adverse effects should be considered especially carefully, because inevitably a number of apparently healthy persons will be subjected to medical tests, and possibly to treatment, with no real long-term improvement in health or longevity. The comparison should be based primarily on the favourable and adverse effects and risks of the interventions. In making choices about (re)allocation of funds between types of intervention, their costs should be weighted against their health effects. Cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis are the methodologies which may be applied in investigating the decision problems [2] [3] [4] . A consideration that is often overlooked is that of (re)distribution of health over the population. For example, cervical cancer is typically a disease of women in lower socioeconomic strata, while breast cancer is one of the few examples of a disease that occurs more frequently in people in higher socioeconomic strata. In view of the present inequality in the distribution of health demonstrated in many countries, cervical cancer screening should deserve some extra attention, but also taking into account that it has a less favourable cost-effectiveness ratio than breast cancer screening. Table 1 shows the predicted favourable and adverse effects of two-yearly breast cancer screening of women aged 50-70 years in the Netherlands [5] . Nationwide screening between 1990 and 2017 is expected to result in a reduction of 6000 breast cancer deaths and a gain of 16 500 years of life per million screening examinations.
Adjustment of the years of life because of changes in quality of life brought about by other effects of screening will have only a small impact: 16 000 quality-adjusted years of life would be gained.
Health effects should be considered in relation to the resources required for establishing those effects. For example, the total cost of 15.8 million screenings for breast cancer in the 27-year period will be 489 million ECU (1 ECU = 2.30 Dfl), i.e. 31 ECU per examination. These costs are partly compensated, since screening will result in a decrease in the costs of management of breast cancer (-249 million ECU), mainly because of the Thirdly, recommending a screening test for specific age screening will, however, have other medical costs during their groups (or other risk categories) will always raise the demand additional years of life. An important complication is that, in from other groups. Experience with cervical cancer screening general, costs and adverse effects occur long before favourable shows that centrally organised screening with a test that does not effects and savings are seen. Time preference is taken into require specialised equipment results in large-scale opportunistic account by using discount rates, calculating present values for screening outside the programme. In the case of cervical cancer, effects, costs and the cost-effectiveness ratio (Table 2) . such opportunistic screening is inefficient, since it involves The time lag between costs and effects may differ considerably predominantly women who are too young and intervals between between screening programmes, e.g. those for cervical cancer, tests that are too short. Coverage, quality control and opportunwhich has a very long preclinical stage, and those for breast istic screening deserve special attention when results and concancer, which has a much shorter preclinical stage. Thus, clusions from an experimental scientific project are transferred discounting will influence the cost-effectiveness of cervical canto a routine population screening service. cer screening in a more unfavourable way than for breast cancer screening.
VERIFYING THE EFFECTIVENESS OF SCREENING The outcomes of a cost-effectiveness study are highly depen-A screening test must undergo rigorous testing and evaluation dent on the specific assumptions on the various aspects of the before it can be judged to be eligible for mass implementation. problem. Hence, results of a sensitivity analysis, in which Basic criteria for judging a screening test were specified by assumptions about all aspects are varied in order to investigate Wilson and Jungner in 1966 [6] . Only a small number of tests their impact on the outcomes, are more informative than just the fuliil the minimal requirements for sensitivity and specifity, and most plausible outcomes. The results of the sensitivity analysis elicit general agreement on the assessment of abnormalities and will indicate how robust the conclusions about the screening on the type of treatment to be used for diagnosed (pre-)invasive programme are.
cancer. These requirements may be investigated on the basis of small-scale (clinical) experiments. REALISTIC SCENARIOS Three well-known biases (lead time, length and self-selection) In making predictions about the potential effects of a screening preclude final testing of a screening test in a non-randomised test, a number of complicating factors should not be overlooked.
design. The theoretical problems of the case-control design have First, the coverage of the population has been found to vary been confirmed empirically [7] . The effectiveness of a screening considerably between countries, screening tests and risk groups test in reducing mortality and morbidity should be demonstrated (e.g. age). Coverage also strongly depends on the way in which in one or more population-based randomised controlled trials. screening is organised: highest coverage is achieved with centralThe absence of evidence based on such trials for the effectiveness ised programmes involving an invitation scheme based on popuof cervical cancer screening by Pap smears has always troubled lation registries (Nordic countries, the Netherlands). In the decision makers. Netherlands, a considerable drop in attendance occurred when Randomised controlled trials are, however, very costly and cervical cancer screening ceased to be organised centrally.
they cannot solve all questions. A single trial generally allows Secondly, thorough quality control of all stages of the screenonly direct conclusions about the effectiveness of the specific ing process, i.e. of the test procedure (mamm ograms, Pap policy used and, depending on the size of the trial, about smear), of the interpretation of the results, and of further differences in effectiveness across age groups. Another inevitable assessment of women with positive results at screening, is problem is that conclusions can be drawn from a randomised mandatory in order to prevent high proportions of false-positive controlled trial only after some 10 years, by which time the and false-negative results and unnecessary, invasive diagnostic screening test or the treatment may have changed considerably. tests. Remarkable differences in referral rates after a positive mammography are found between the U.S.A. and the U.K. on CHOOSING A SCREENING POLICY the one hand, and Sweden, Finland and the Netherlands on the Once effectiveness has been demonstrated, further evidence other. Similar differences might occur within one country in the of the effectiveness in different age groups or with different absence of good quality control.
screening intervals can be obtained from case-control studies. For a comprehensive evaluation of screening policies (age Table 2 . Costs and effects of breast cancer screening, the Netherlands groups, intervals, risk groups) with respect to health effects, (see Table 1 ): comparison of outcomes with and without discounting risks and costs, simulation models are powerful tools, as all important factors can be taken into account. The predictions Discount rate shown in Tables 1 and 2 The decision-orientated approach is still useful after the Cancer Screening Activitiesscreening test has been implemented in a population-based early detection programme. The results of the programme (participation, detection rate, stage distribution, interval cancers, costs) should be carefully registered and monitored and can be compared with expectations made at the outset. Major discrepancies or new developments in diagnosis and therapy can be investigated by computer simulation, which will lead to recommendations about adaptations of the screening policy, conducting new pilot studies or sometimes even randomised controlled trials.
9.
